HERPETIC FEVER VIRUS VACCINES Russian patent published in 2016 - IPC C12N7/01 A61K39/245 A61P31/22 

FIELD: biotechnologies.

SUBSTANCE: replication-deficient, dominant and negative recombinant virus of herpetic fever 2, the vaccine and the method of patient immunisation against the infection HSV-1 or HSV-2 are offered. The recombinant virus contains two sequences coding D HSV-2 glycoprotein, linked with ICP4 promoters in the genome, the latter are connected with the sequences of tetracycline operators, and two sequences coding UL9-C535C protein which are linked with hCMV promoters linked with the sequences of tetracycline operators. Note that the virus doesn't contain the sequence coding ICP0 protein. The vaccine containing the named recombinant virus is safe and efficient against the infections HSV-1 or HSV-2 due to expression of the dominant and negative form of UL9-C535C polypeptide and use of tetracycline-induced activation and deactivation of genes. The method of immunisation of patients against HSV-1 or HSV-2 using the offered vaccine is also offered.

EFFECT: offered vaccine and the method of patient immunisation can be used in medicine for transformation or suppression of breakout of HSV-1 or HSV-2.

17 cl, 19 dwg, 1 tbl, 1 ex